Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecirasib in KRAS G12C-mutated solid tumors
NCT06008288Phase 2Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib in pancreatic cancer (PC), solid tumor, sponsored by Allist Pharmaceuticals. Started Oct 2023; status: recruiting.
02
Drugs
glecirasib
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT06008288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008288.